+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030- Product Image
Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030- Product Image
Sale

Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081818
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Scene for RSV Vaccination in Older Adults

Respiratory syncytial virus (RSV) poses a significant health threat to the elderly, often leading to serious respiratory complications that can result in hospitalizations and elevated mortality rates. As demographic shifts drive a growing population aged 65 and above, the urgency to develop and deploy effective vaccines tailored to this cohort has never been higher. Advances in immunology and vaccine technology have converged with increased public health awareness to create a dynamic environment where novel prevention strategies can gain rapid foothold.

Against this backdrop, the market for RSV vaccines designed specifically for older adults is poised for transformative growth. In recent years, clinical trials have demonstrated promising safety and efficacy profiles across multiple platforms, ranging from traditional subunit approaches to next-generation mRNA formulations. At the same time, evolving regulatory pathways and reimbursement frameworks are influencing the speed at which these immunizations can reach end users. This report synthesizes the latest developments, evaluates competitive positioning, and lays the foundation for data-driven decision-making by industry leaders and policy makers alike.

Navigating the Shifting Tides of the RSV Vaccine Ecosystem

The RSV vaccine landscape is undergoing rapid evolution driven by breakthroughs in platform technology and shifts in healthcare delivery. Major players are leveraging messenger RNA platforms that have proved successful in other viral vaccines, while traditional recombinant and subunit methods remain central to combination strategies aiming to broaden immune responses. At the same time, the refinement of intranasal administration is unlocking new opportunities for needle-free immunization, potentially improving uptake rates among seniors who often exhibit needle aversion.

Distribution models are also being reimagined. Hospital pharmacies and ambulatory surgical centers are collaborating more closely to streamline on-site immunization clinics, while digital channels and online pharmacies are enabling remote ordering and home administration support. This integration of digital and clinical infrastructure is reshaping patient pathways, fostering closer engagement between healthcare providers and vaccine manufacturers, and creating a feedback loop that accelerates iterative improvement of dosing regimens and patient education materials.

Assessing the 2025 United States Tariffs and Their Sectoral Fallout

The implementation of new tariffs on pharmaceutical imports in 2025 has introduced both challenges and strategic inflection points for the RSV vaccine value chain. Increased duties on critical reagents and raw materials have elevated manufacturing costs, compelling vaccine producers to revisit supply agreements and negotiate price adjustments with raw material suppliers. Consequently, production facilities are exploring geographic diversification to mitigate exposure to any single tariff jurisdiction.

On the distribution side, higher import costs are translating into upward pressure on wholesale and retail pricing. Payers and providers are engaging in more rigorous cost-benefit analyses, demanding evidence of real-world effectiveness to justify premium pricing. Manufacturers have responded by investing in local fill-finish capacity and forging partnerships with domestic contract manufacturing organizations to contain overall cost inflation. As a result, decision makers must balance the imperative of ensuring affordable access for vulnerable elderly populations with the necessity of sustaining R&D investments.

Uncovering Diverse Market Segments Driving RSV Adoption

A nuanced understanding of end users reveals that ambulatory surgical centers are enhancing their preventive care offerings by integrating RSV vaccination into routine preoperative evaluations, while clinics are prioritizing immunization during annual wellness visits to drive adherence among older adults. Meanwhile, hospitals are launching dedicated immunization units, recognizing that in-patient vaccination opportunities can reduce readmission rates and improve patient outcomes.

The dynamics of distribution channels show that hospital pharmacy operations are expanding their cold-chain logistics to accommodate diverse vaccine formulations. Online pharmacies are capitalizing on telehealth consultations to guide older patients through dosing schedules, while retail pharmacies are collaborating with primary care networks to create immunization hubs that merge convenience with clinical oversight.

Within vaccine types, live attenuated platforms are being investigated for mucosal immunity benefits, mRNA approaches continue to push the frontiers of rapid manufacturing and antigen design, recombinant vaccines offer scalable production advantages, and subunit formulations are focusing on adjuvant innovations to enhance immune response. Each modality presents a distinct value proposition in terms of efficacy, storage requirements, and manufacturing footprint.

Route of administration is also shaping clinical protocols. Intramuscular injections remain the backbone of current immunization programs due to established safety profiles, while intranasal sprays are emerging as a less invasive alternative that could drive higher uptake among needle-averse seniors. Evaluation of these routes is ongoing across diverse real-world settings.

Age cohort insights indicate that individuals aged 65 to 74 years are early adopters of preventive measures, those in the 75 to 84 bracket benefit from targeted educational campaigns, and the 85 and above segment requires tailored dosing support and in-home administration models to address mobility constraints.

Mapping Global Demand Patterns Across Key Regions

In the Americas, strong public-private collaborations and established immunization programs have laid a foundation for rapid adoption of novel RSV vaccines. Health authorities are issuing clear guidelines for elderly immunization, and payers are aligning reimbursement policies to support broad coverage. As a result, vaccine manufacturers are prioritizing regional supply chain resilience and engaging in locally based clinical studies to address demographic nuances.

Across Europe, the Middle East and Africa, heterogeneous healthcare infrastructures and varying regulatory landscapes present both opportunities and complexities. In Western Europe, centralized procurement mechanisms and robust surveillance systems facilitate streamlined launches, whereas in parts of the Middle East and Africa, partnerships with global health organizations are pivotal to scale distribution in resource-limited settings. Stakeholders in these regions are also exploring tiered pricing structures to ensure equitable access.

In Asia-Pacific markets, rapid economic growth and an expanding elderly population are driving heightened demand. Governments are investing in domestic manufacturing capabilities and regulatory harmonization efforts to expedite approval processes. Collaboration between multinational biopharmaceutical companies and local manufacturers is accelerating technology transfer, positioning countries in the region as both production hubs and major consumer markets.

Spotlight on Leading Innovators in Elderly RSV Vaccines

Leading pharmaceutical innovators are at the forefront of the race to deliver RSV vaccines tailored to older adults. One major biopharma leader has leveraged its extensive global distribution network to secure early market entry for its recombinant product, while another has harnessed its mRNA expertise to accelerate time-to-clinic for a novel candidate. Strategic alliances between vaccine developers and contract manufacturing organizations are strengthening supply resilience and enabling flexible scale-up.

Smaller biotech firms are carving out niches by focusing on intranasal platforms and partnering with academic institutions to access specialized adjuvant technologies. Meanwhile, established vaccine powerhouses are deepening their pipelines through acquisitions and licensing agreements that expand their platform portfolios. Across the board, companies are investing in real-world evidence generation to build payer confidence and optimize value demonstration in elderly cohorts.

Strategic Imperatives for Vaccine Stakeholders

Industry leaders should prioritize diversification of manufacturing footprints to shield operations from geopolitical disruptions and tariff fluctuations. By investing in modular production facilities and forging partnerships across multiple regions, vaccine producers can maintain flexible supply chains and control costs. Simultaneously, bolstering real-world evidence programs will strengthen negotiations with payers and support premium pricing for high-value products.

Engagement strategies that emphasize education and outreach among healthcare providers will be crucial to drive uptake, especially for novel routes such as intranasal delivery. Comprehensive training modules and digital support tools can empower clinic staff and pharmacists to address patient concerns effectively. In parallel, adaptive reimbursement models-such as outcome-based contracts-can align incentives across stakeholders and ensure that elderly populations receive timely access without straining payer budgets.

Rigorous Methodology Underpinning the Analysis

This analysis is underpinned by a rigorous multi-step methodology that integrates both primary and secondary research. Initial insights were drawn from in-depth interviews with senior executives, clinical experts, and payers across North America, Europe, and Asia-Pacific. These qualitative inputs were triangulated against a comprehensive review of peer-reviewed publications, regulatory filings, and pharmaceutical patent databases.

Market segmentation and regional demand projections were validated through proprietary datasets and cross-checked with public health registries. Company profiles and competitive dynamics were refined via proprietary deal trackers and conference presentations. All data underwent a multi-layered quality assurance process, including fact-checking, consistency reviews, and alignment with current regulatory guidelines. The result is a robust and transparent foundation for strategic planning in the RSV vaccine sector.

Key Takeaways Shaping the Future of Elderly RSV Immunization

As the burden of respiratory syncytial virus among older adults garners heightened attention, the landscape of vaccine innovation is at an inflection point. Technological advancements spanning mRNA platforms, recombinant methods, and novel delivery systems are converging to offer new avenues for protection. Simultaneously, evolving regulatory frameworks and tariff dynamics are reshaping the economics of production, distribution, and pricing.

By examining segmentation across end users, distribution channels, vaccine types, routes of administration, and age cohorts, stakeholders can pinpoint high-value opportunities and anticipate emerging challenges. Regional variations in healthcare infrastructure and payer policies further underscore the need for tailored market entry strategies. Overall, the confluence of scientific breakthroughs and strategic imperatives presents a compelling case for investment and collaboration in the development and commercialization of RSV vaccines for the elderly.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Vaccine Type
    • Live Attenuated
    • mRNA
    • Recombinant
    • Subunit
  • Route Of Administration
    • Intramuscular
    • Intranasal
  • Age Cohort
    • 65-74 Years
    • 75-84 Years
    • 85 Years And Above
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Moderna, Inc.
  • BioNTech SE
  • Bavarian Nordic A/S
  • Novavax, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • CureVac N.V.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Formulation
8.1. Introduction
8.2. Inactivated Vaccines
8.3. Live Attenuated Vaccines
8.4. Recombinant Vaccines
8.4.1. Protein-Based
8.4.2. Virus-Like Particles
8.5. RNA-Based Vaccines
9. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Administration Route
9.1. Introduction
9.2. Injectable Vaccines
9.3. Nasal Sprays
9.4. Oral Vaccines
10. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Dosage
10.1. Introduction
10.2. Multiple Dosages
10.2.1. Booster Shots
10.3. Single Dose
11. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Components
11.1. Introduction
11.2. Adjuvants
11.3. Antibiotics
11.3.1. Neomycin-Free
11.3.2. Polymyxin-Free
11.4. Preservatives
11.4.1. Alcohol-Free
11.4.2. Mercury-Free
11.5. Stabilizers
11.5.1. Amino Acids
11.5.2. Sugars
12. Respiratory Syncytial Virus Vaccine for the Elderly Market, by End-User
12.1. Introduction
12.2. Home Healthcare
12.3. Hospitals
12.4. Nursing Homes
12.5. Pharmacies
12.6. Primary Care Clinics
13. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Disease Burden
13.1. Introduction
13.2. Cardiovascular Conditions
13.3. Chronic Respiratory Conditions
13.3.1. Asthma
13.3.2. Chronic Obstructive Pulmonary Disease
13.4. Weakened Immune Systems
14. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Age Group
14.1. Introduction
14.2. 60-69 Years
14.3. 70-79 Years
14.4. 80+ Years
15. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Distribution Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Technology
16.1. Introduction
16.2. Biotech Innovations
16.2.1. Nanotechnology
16.3. Conventional Technology
16.4. Synthetic Strategies
17. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Type
17.1. Introduction
17.2. Prophylactic
17.3. Therapeutic
18. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Manufacturing Process
18.1. Introduction
18.2. Advanced Genetic Techniques
18.3. Traditional Methods
19. Americas Respiratory Syncytial Virus Vaccine for the Elderly Market
19.1. Introduction
19.2. Argentina
19.3. Brazil
19.4. Canada
19.5. Mexico
19.6. United States
20. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market
20.1. Introduction
20.2. Australia
20.3. China
20.4. India
20.5. Indonesia
20.6. Japan
20.7. Malaysia
20.8. Philippines
20.9. Singapore
20.10. South Korea
20.11. Taiwan
20.12. Thailand
20.13. Vietnam
21. Europe, Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Market
21.1. Introduction
21.2. Denmark
21.3. Egypt
21.4. Finland
21.5. France
21.6. Germany
21.7. Israel
21.8. Italy
21.9. Netherlands
21.10. Nigeria
21.11. Norway
21.12. Poland
21.13. Qatar
21.14. Russia
21.15. Saudi Arabia
21.16. South Africa
21.17. Spain
21.18. Sweden
21.19. Switzerland
21.20. Turkey
21.21. United Arab Emirates
21.22. United Kingdom
22. Competitive Landscape
22.1. Market Share Analysis, 2024
22.2. FPNV Positioning Matrix, 2024
22.3. Competitive Analysis
22.3.1. Ablynx (A Sanofi Company)
22.3.2. AstraZeneca Plc (In collaboration with Sanofi)
22.3.3. Bavarian Nordic A/S
22.3.4. Codagenix, Inc.
22.3.5. GlaxoSmithKline plc
22.3.6. Johnson & Johnson (Janssen Pharmaceuticals)
22.3.7. MedImmune (A subsidiary of AstraZeneca)
22.3.8. Meissa Vaccines, Inc.
22.3.9. Merck & Co., Inc.
22.3.10. Moderna, Inc.
22.3.11. Novavax, Inc.
22.3.12. Pfizer Inc.
22.3.13. ReVax Ltd.
22.3.14. ReViral Ltd.
22.3.15. Sanofi S.A.
22.3.16. Valneva SE
22.3.17. Vaxart, Inc.
22.3.18. Zydus Cadila
23. ResearchAI
24. ResearchStatistics
25. ResearchContacts
26. ResearchArticles
27. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 32. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 38. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BOOSTER SHOTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NEOMYCIN-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY POLYMYXIN-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ALCOHOL-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MERCURY-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SUGARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NURSING HOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY WEAKENED IMMUNE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 60-69 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 70-79 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 80+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CONVENTIONAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SYNTHETIC STRATEGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADVANCED GENETIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TRADITIONAL METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 125. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 127. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 128. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 129. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 130. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 131. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 132. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 133. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 134. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 136. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 137. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 141. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 148. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 154. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 217. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 218. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 219. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 220. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 221. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 222. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 223. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 224. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 225. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 226. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 228. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 229. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 233. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 234. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 235. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 237. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 238. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 239. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 240. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 241. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 242. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 243. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 244. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 246. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 247. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 251. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Respiratory Syncytial Virus Vaccine for the Elderly market report include:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Moderna, Inc.
  • BioNTech SE
  • Bavarian Nordic A/S
  • Novavax, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • CureVac N.V.

Related Topics

Related Reports

Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine for Children Market by Vaccine Type, Distribution Channel, Age Group, Dose Regimen, End User - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Vaccine for Children Market by Vaccine Type, Distribution Channel, Age Group, Dose Regimen, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.